Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to evaluate ivonescimab in combination with GSK's investigational B7-H3 antibody drug conjugate, risvutatug rezetecan, across multiple solid tumour settings, including small cell lung cancer.
Ivonescimab is a novel, investigational PD-1 / VEGF bispecific antibody.
The collaboration with GSK aims to assess the safety profile and potential anti-tumour activity of the combination therapy.
Under the agreement, Summit will supply ivonescimab, while GSK will oversee day-to-day clinical trial operations. Each company will retain rights to its respective product, and the collaboration is structured as non-exclusive.
Clinical trials are expected to begin dosing patients in mid-2026.
Leo Cancer Care invests in children's experience of radiotherapy, following world-first treatments
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
FDA approves WELIREG and LENVIMA combination for previously treated advanced renal cell carcinoma
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
UChicago Medicine completes construction phase of new cancer facility
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Astellas doses first patient in Phase 3 lung cancer study
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AbbVie and Iambic agree collaboration for discovery and development of small molecule therapies
Grunenthal to acquire Stivarga cancer treatment
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS